Krystal Biotech (KRYS) PT Raised to $111 at Cowen

November 29, 2021 12:27 PM EST
Get Alerts KRYS Hot Sheet
Price: $68.52 +0.84%

Rating Summary:
    11 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 12 | New: 20
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cowen analyst Ritu Baral raised the price target on Krystal Biotech (NASDAQ: KRYS) to $111.00 (from $89.00) while maintaining an Outperform rating.

The analyst commented, "KRYS announced positive topline data from the Ph3 GEM-3 trial of Vyjuvek (fka B-VEC) in DEB. The study met its primary endpoint of 100% wound healing at 6 mo., with 67% of wounds treated with Vyjuvek achieving complete wound healing compared to 22% with pbo (absolute Δ 45.8%; p<0.005 by McNemar). Detailed data and BLA filing are expected in 1H22. We remain at Outperform, increasing our PT to $111."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cowen & Co